Issues Facing TB Control (7) Multiple Drug-Resistant Tuberculosis

Pablos-Mendez A , Raviglione MC , Laszlo A Global surveillance for anti-TB-drug resistance, 1994–1997 N Engl J Med 1998; 338: 1641–1649

Laszlo A , Rahman M , Raviglione M , Bustreo F and the WHO/IUATLD Network of Supranational Reference Laboratories. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis 1997; 1: 231–238

Cohn DL , Bustreo F , Raviglione MC . Drug resistance in tuberculosis: review of the worldwide situation and WHO/IUATLD's Global Surveillance Project. Clin Infect Dis 1997; 24 (Suppl. 1): S121–S130

Farmer P , Bayona J , Becerra M , Furin J , Henry C , Hiatt H The dilemma of MDRTB in the global era. Int J Tuberc Lung Dis 1998; 2: 869–76

Farmer P , Kim JY . Community-based approaches to the control of multidrug-resistant tuberculosis: introducing “DOTS-PLUS”. Br Med J 1998; 317: 671–674

Communicable Diseases. Coordination of DOTS-PLUS pilot projects for the management of MDRTB Proceedings of a Meeting. Geneva, 29 January 1999. Edited by: Espinal MA Raviglione MC . Geneva, 1999. WHO/TB/99.262

World Health Organization WHO Tuberculosis Programme. Framework for effective tuberculosis control. WHO/TB/94.179, Geneva, 1994

World Health Organization. Global Tuberculosis Programme (Raviglione M, Schmidt S, Nunn P, Dye C, Spinaci S, Chaulet P, Grzemska M, Hanson C, Kumaresan J, Levy M, Luelmo F, Tayler E, Kochi A) Global tuberculosis control. WHO Report 1997. Geneva, Switzerland, WHO/TB/97.225

World Health Organization. Global Tuberculosis Programme (Netto EM, Dye C, Schmidt S, Raviglione M). Global tuberculosis control. WHO Report 1998. Geneva, Switzerland, WHO/TB/98.237

World Health Organization. Communicable Diseases (Netto EM, Dye C, Raviglione M). Global tuberculosis control. WHO Report 1999 Geneva, Switzerland, WHO/CPC/TB/99.259

Raviglione MC , Dye C , Schmidt S , Kochi A for the WHO Global Surveillance and Monitoring Project. Assessment of worldwide tuberculosis control. Lancet 1997; 350: 624–629

Styblo K , Raviglione MC . Tuberculosis, public health aspects. In Dulbecco R. , ed. “Encyclopedia of human biology”, Second Edition, Vol. 8. Academic Press, 1997

Enarson DA . The International Union Against Tuberculosis and Lung Disease model National Tuberculosis Programme. Tuberc Lung Dis 1995; 76: 95–99

World Health Organization. Treatment of tuberculosis. Guidelines for National Programmes. Second Edition 1997. Geneva, 1997. WHO/TB/97.220

Ministerio de Salud, Dirección General de Salud de Las Personas, Dirección del Programa Nacional de Control de Enfermedades Transmisibles Control de la Tuberculosis. Seminario Taller: Evaluatión del Programa Nacional de Control de la Tuberculosis en el Perú-año 1997, Lima, Perú

Norval P-Y , San K Kim , Bakhim T , Rith DN , Ahn DI , Blanc L. DOTS in Cambodia. Int J Tuberc Lung Dis 1998; 2: 44–51

China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smearpositive tuberculosis. Lancet 1996; 347: 358–62

Kumaresan JA , Ahsanali AKMD , Parkkali LM . Tuberculosis control in Bangladesh: success of the DOTS strategy. Int J Tuberc Lung Dis 1998; 2: 992–998

Pablos-Méndez A , Laszlo A , Bustreo F , Binkin N , Cohn DL , Lambregts-van Weezembeek C , Kim SJ , Chaulet P , Nunn P , Raviglione MC and the members of the WHO/IUATLD Global Project on Antituberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland, 1997. WHO/TB/97.229

WHO/IUATLD Global Working Group on Antimicrobial Drug Resistance Surveillance. Guidelines for surveillance of drug resistance in tuberculosis, 1997. Edited by Bustreo F , Pablos-Mendez A , Raviglione M , Murray J , Trébucq A , Rieder H . Geneva, Switzerland, WHO/TB/96.216

Hong YP , Kim SJ , Lew WJ , Lee EK , Han YC . The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuber Lung Dis 1998; 2: 27–36

Kim SJ , Bai SH , Hong YP . Drug-resistant tuberculosis in Korea. Int J Tuber Lung Dis 1997; 1: 302–8

Espinal M , Dye C , Raviglione M , Kochi A. Rational “DOTS Plus” for the control of MDRTB. Int J Tuber Lung Dis 1999; 3: 561–3

Chaulet P. Tuberculose et transition épidémiologique: le cas de l'Algérie. Annales de l'Institut Pasteur 1993; 4: 181–187

Espinal MA , Kim SJ , Hong YP Treatment outcome of multidrug resistant (MDR) tuberculosis (TB) cases under programme conditions. Proceedings of the Global Congress on Lung Health, 29th World Conference of International Union Against Tuberculosis and Lung Disease, IUATLD/UICTMR. Abstract 428-PC Bangkok, Thailand, 23–26 November 1998. Int J Tuberc Lung Dis 1998; 2 (suppl. 2): S371

Frieden TR , Fujiwara PI , Washko RM , Hamburg MA . Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333: 229–33

Goble M , Iseman MD , Madsen LA Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527–32

Telzak EE , Sepkowitz K , Alpert P Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 33: 907–911

Park SK , Kim CT , Song SD . Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2: 877–884

Crofton J , Chaulet P , Maher D Guidelines for the management of drug-resistant tuberculosis. Geneva, 1997. WHO/TB/96.210

Iseman MD . Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784–791

Communicable Disease. Report. Multidrug resistant tuberculosis - Basis for the development of an evidence-based case-management strategy for MDRTB within the WHO's DOTS strategy. Proceedings of 1998 Meetings and Protocol Recommendations. Edited by Espinal MA . Geneva, 1999. WHO/TB/99.260